title: [Use of monoclonal antibodies in prophylaxis and treatment of acute and chronic graft-versus-host disease in 2011].
abstract: Allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice of hematologic malignancies. Acute graft versus host disease (GvHD) is common after HSCT and directly related to graft versus leukemia effect. Little progress has been done in the treatment of acute GvHD. The first line treatment is usually high-dose steroids for patients presenting grade II or more GvHD. However, 40% of those patients are resistant to this treatment. Several approaches using monoclonal antibodies against cytokines or other molecules involved in the physiopathology of GvHD have been used. The aim of this review is an updated overview of the mainly used monoclonal antibodies in the prophylaxis or treatment of GvHD (e.g., anti-CD52, anti-TNFα, anti-CD25, anti-LFA3 and anti-CD20).
authors.affiliation: Hôpital Saint-Louis, Paris, France.
authors.forename: Aliénor
authors.initials: A
authors.lastname: Xhaard
authors.forename: Eric
authors.initials: E
authors.lastname: Hermet
authors.forename: Jacques-Olivier
authors.initials: JO
authors.lastname: Bay
authors.forename: Régis
authors.initials: R
authors.lastname: Peffault de Latour
mesh_terms: D000208:Acute Disease; D000077944:Alefacept; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D002908:Chronic Disease; D000077561:Daclizumab; D000068800:Etanercept; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D000069283:Rituximab; D014184:Transplantation, Homologous
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D000074323:Alemtuzumab; D000069283:Rituximab; D000069285:Infliximab; D000077561:Daclizumab; D000077944:Alefacept; D000068800:Etanercept